Factor This Power Engineering
Live Events
DTECH⢠Events
POWERGEN®
Calendar
Resource Center
Webinars
Podcasts
White Papers
Contribute Content
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Project Development
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Resource Center
Webinars
Podcasts
Whitepapers
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
345.42
+7.06 (+2.09%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
61
62
Next >
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Looking At Amgen's Recent Unusual Options Activity
↗
January 09, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
January 08, 2024
Via
Benzinga
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
↗
January 08, 2024
Via
Benzinga
Looking At Amgen's Recent Unusual Options Activity
↗
January 05, 2024
Via
Benzinga
Amgen Inc. (NASDAQ: AMGN) Records 52-Week High Tuesday Morning
January 02, 2024
Via
Investor Brand Network
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
↗
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
A Rough Start To 2024 What Might Be In Store For The Rest Of 2024?
↗
January 07, 2024
The market was weighed down by several negative factors that began before the bell even rang at Broad and Wall on the first trading day of this New Year.
Via
Talk Markets
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
↗
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Amgen's Options: A Look at What the Big Money is Thinking
↗
December 28, 2023
Via
Benzinga
Analyzing Amgen In Comparison To Competitors In Biotechnology Industry
↗
December 25, 2023
Via
Benzinga
Is NASDAQ:AMGN a Good Fit for Dividend Investing?
↗
December 22, 2023
Why AMGEN INC (NASDAQ:AMGN) is a Top Pick for Dividend Investors.
Via
Chartmill
10 Health Care Stocks Whale Activity In Today's Session
↗
January 04, 2024
Via
Benzinga
Will the Biotech sector sustain its momentum in 2024?
January 04, 2024
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.
Via
MarketBeat
Topics
ETFs
Revenge of the Boring Stocks! Dividends Are Sexy Again.
↗
January 03, 2024
Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now.
Via
InvestorPlace
Did Santa Claus Claus Leave Town A Day Early?
↗
January 02, 2024
With the exception of the Dow, stocks are down hard to begin the new calendar year.
Via
Talk Markets
Topics
Stocks
Spotlight on Amgen: Analyzing the Surge in Options Activity
↗
December 21, 2023
Via
Benzinga
Looking Into Amgen's Recent Short Interest
↗
December 20, 2023
Via
Benzinga
In-Depth Examination Of 18 Analyst Recommendations For Amgen
↗
December 19, 2023
Via
Benzinga
Is Amgen Stock a Buy Now?
↗
December 17, 2023
Boring businesses can be successful, too.
Via
The Motley Fool
Dogs Of The Dow: Top 10 Highest Yielding Dow Jones Stocks, How To Get Dividends Of 3% to 7.4% In 2024
↗
January 02, 2024
Twenty eight of the 30 Dow Jones Industrial Average components pay out dividends. A look at the top ten highest dividend yields.
Via
Benzinga
Topics
Stocks
3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar
↗
January 01, 2024
I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with.
Via
The Motley Fool
Topics
ETFs
Retirement
Amgen Stock Sees Relative Strength Rating Improve To 74
↗
December 29, 2023
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74.
Via
Investor's Business Daily
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
↗
December 29, 2023
There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.
Via
The Motley Fool
Topics
Stocks
Full Approval For Amgen's Flagship Cancer Drug Lumakras Pushed For Around Four Years
↗
December 26, 2023
Amgen Inc (NASDAQ: AMGN) announced that the FDA has reviewed the company's supplemental New Drug Application, seeking full approval of the KRAS-blocking drug
Via
Benzinga
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
↗
December 21, 2023
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."
Via
InvestorPlace
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
↗
December 20, 2023
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy.
Via
InvestorPlace
Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst
↗
December 19, 2023
Amgen, Inc. (NASDAQ: AMGN) shares have been in focus amid developments in the AI-powered healthcare space.
Via
Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
December 19, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Healthcare Sector Stocks: Consistent Above-Average Growth And Income
↗
December 18, 2023
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records.
Via
Talk Markets
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
61
62
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
